Evotec has announced that it has been awarded a new $2.9m grant by the Gates Foundation to continue developing and deploying its human stem cell-based New Approach Methodologies (NAMs), which aim to identify potential developmental toxicity risks before drug candidates progress to clinical testing.
The platform combines human induced pluripotent stem cell (hiPSC) models with high-throughput screening, automation and high-content imaging to investigate how compounds may affect aspects of human prenatal development.
The new award extends a Gates Foundation-funded project launched in 2023.
During the initial three-year collaboration, Evotec screened more than 5000 compounds across nine global health research programmes, generating human-relevant safety data to inform decisions about which candidates should progress.
The approach could help researchers identify potential developmental safety liabilities earlier in drug discovery, reducing the risk of costly late-stage development failures.
Evotec said that it could also support the wider adoption of NAMs as alternatives or complements to traditional animal-based testing.
Evotec expands its drug discovery and technology capabilities
The grant comes amid a period of strategic transformation and continued investment in Evotec's technology platforms.
In March of this year, the company announced its Horizon restructuring programme, designed to streamline its global operations, consolidate scientific expertise into dedicated Centres of Excellence and focus its business on drug discovery and preclinical development.
The programme targets approximately €75m in annual run-rate savings by the end of 2027.
Evotec has also expanded its research collaborations, including an agreement with Odyssey Therapeutics to apply its AI-enabled discovery platform and screening capabilities to autoimmune and inflammatory disease programmes.
In June, its Just – Evotec Biologics business launched J.TRAIN, a service designed to help biopharma companies implement continuous biologics manufacturing technology at their own facilities.
The company also entered a research collaboration with Plectonic in September to explore next-generation T-cell-engaging approaches for solid tumours, combining Evotec's BiTco platform with Plectonic's LOGIBODY technology.